0000000000303641

AUTHOR

Sigurd Knaub

showing 2 related works from this author

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance

2008

Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate P, have been developed to help patients achieve and maintain normal haemostasis. Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for th…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHaemophilia AHemophilia AHaemophiliaHaemate P; Humate-P; von Willebrand disease; von Willebrand factor; haemophilia; factor VIIIVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansDosingDesmopressinHematologybiologybusiness.industryHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesCoagulationImmunologybiology.proteinSafetybusinessSettore MED/15 - Malattie del Sanguemedicine.drug
researchProduct

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate® in Children Under 6 Years of Age with Inherit…

2011

Abstract Abstract 3330 Introduction: Wilate® is a new-generation plasma-derived concentrate of von Willebrand factor (VWF) and factor VIII (FVIII) developed for treatment of patients with von Willebrand disease (VWD) and haemophilia A. The objective of this study was to assess efficacy, safety and immunogenicity of Wilate in children below 6 years of age with inherited VWD. Methods: The prospective, multi-centre trial included patients with inherited VWD of any type below 6 years of age with insufficient response to DDAVP. Any clinical event requiring VWF/FVIII concentrate treatment within 1 year was treated with Wilate. Efficacy was recorded by using a 4-point VRS and in vivo recovery of F…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsbiologybusiness.operationbusiness.industryImmunogenicityImmunologyCell BiologyHematologyHaemophiliamedicine.diseaseOctapharmaBiochemistryVon Willebrand factorTolerabilityhemic and lymphatic diseasesInternal medicinemedicinebiology.proteinVon Willebrand diseaseDosingbusinessAdverse effectBlood
researchProduct